| Literature DB >> 28088221 |
Salim Abraham Barquet-Muñoz1, Gabriel Jaime Rendón-Pereira2, Denise Acuña-González1, Monica Vanessa Heymann Peñate3, Luis Alonso Herrera-Montalvo4, Lenny Nadia Gallardo-Alvarado5, David Francisco Cantú-de León6, René Pareja7.
Abstract
BACKGROUND: Cervical cancer (CC) occupies fourth place in cancer incidence and mortality worldwide in women, with 560,505 new cases and 284,923 deaths per year. Approximately, nine of every ten (87%) take place in developing countries. When a macroscopic nodal involvement is discovered during a radical hysterectomy (RH), there is controversy in the literature between resect macroscopic lymph node compromise or abandonment of the surgery and sending the patient for standard chemo-radiotherapy treatment. The objective of this study is to compare the prognosis of patients with CC whom RH was abandoned and bilateral pelvic lymphadenectomy and para-aortic lymphadenectomy was performed with that of patients who were only biopsied or with removal of a suspicious lymph node, treated with concomitant radiotherapy/chemotherapy in the standard manner.Entities:
Keywords: Abandoned radical hysterectomy; Cervical cancer; Systematic lymphadenectomy
Mesh:
Year: 2017 PMID: 28088221 PMCID: PMC5237563 DOI: 10.1186/s12957-016-1067-2
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinical and pathological characteristic of patients with cervical cancer with abandoned hysterectomy (N = 42)
| Countrya | |
| Mexico (INCan) | 19 (45) |
| Colombia (ICLA) | 23 (55) |
| Age (years)b | 46 (40.8–56) |
| BMIb | 25.68 (23.2–29.5) |
| Prior imaging studya | 20 (42.6) |
| Ultrasonography | 7 (35) |
| CT | 10 (50) |
| MRI | 3 (15) |
| Histologya | |
| Squamous | 24 (57.1) |
| Adenocarcinoma | 12 (28.6) |
| Adenosquamous | 4 (9.5) |
| Others | 2 (4.8) |
| Clinical stagea | |
| IB1 | 37 (88.1) |
| IB2 | 2 (4.8) |
| IIA1 | 3 (7.1) |
| Tumor size (cm)b | 3.0 (2.0–4.0) |
| Tumor gradea | |
| Well-differentiated | 14 (33.3) |
| Moderately differentiated | 17 (40.1) |
| Poorly differentiated | 11 (26.2) |
| LVSIa | 5 (12) |
| Reason for abandonmenta | |
| Pelvic lymph node affectation | 19 (45.2) |
| Para-aortic lymph node affectation | 9 (21.4) |
| Parametrial involvement | 7 (16.7) |
| Others | 7 (16.7) |
| Type of lymphadenectomya | |
| Pelvic | 14 (33.3) |
| Para-aortic | 6 (14.3) |
| Tumor biopsy | |
| Pelvic | 19 (45.2) |
| Para-aortic | 14 (33.3) |
BMI body mass index, CT computed tomography, MRI magnetic resonance imaging, LVSI lymphovascular space involvement
a N (relative frequency)
bMedian (interquartile range)
Comparison of patients group with pelvic lymph node surgery
| Tumor removal and/or pelvic biopsy | Pelvic lymphadenectomy |
| |
|---|---|---|---|
| Countrya | |||
| Mexico (INCan) | 10 (52.6) | 2 (14.3) | 0.02 |
| Colombia (ICLA) | 9 (47.4) | 12 (85.7) | |
| Age (years)b | 45 (35-53) | 45.5 (40-54.3) | 0.55 |
| BMI b | 27.4 (25.3–31.1) | 24.6 (22.4–25.4) | 0.01 |
| Histologya | |||
| Squamous | 9 (47.4) | 9 (64.3) | 0.22 |
| Adenocarcinoma | 5 (26.3) | 5 (35.7) | |
| Adenosquamous | 3 (15.8) | 0 | |
| Others | 2 (10.5) | 0 | |
| Initial clinical stagea | |||
| IB1 | 18 (94.7) | 13 (92.9) | 0.82 |
| IB2 | 1 (5.3) | 1 (7.1) | |
| Tumor size (cm)b | 3 (1.6–4) | 3 (2–4) | 0.63 |
| Tumor gradea | |||
| Well-differentiated | 4 (21.1) | 7 (50) | 0.05 |
| Moderately differentiated | 7 (36.8) | 6 (42.9) | |
| Poorly differentiated | 8 (42.1) | 1 (7.1) | |
| LVSIa | 3 (15.8) | 2 (14.3) | 0.74 |
| Systematic PALa | 1 (5.3) | 5 (35.7) | 0.062 |
| BPRa | 11 (57.9) | 3 (21.4) | 0.073 |
| PR positive | 17 (89.5) | 12 (85.7) | NS |
| Surgical time (min)b | 150 (120–190) | 165 (103.8–198.8) | 0.69 |
| Blood loss (mm)b | 100 (70–250) | 100 (57.5–212.5) | 0.78 |
| Blood transfusiona | 1 (0.05) | 1 (0.07) | 0.82 |
| Others complicationsa | 1 (0.05) | 1 (0.07) | 0.82 |
| Hospital stay (days)b | 2 (2–2) | 2 (2–3.3) | 0.19 |
| Neoadjuvant treatment term (weeks)b | 10 (7.5–14) | 8.8 (8.1–11) | 0.57 |
| Recurrencea | 7 (26.8) | 2 (14.3) | 0.15 |
| Local | 1 (14.3) | 0 | |
| Regional | 6 (85.7) | 2 (100) | |
| Distance | 0 | 0 | |
Confidence interval 95%
BMI body mass index, Mod moderate, LVSI lymphovascular space involvement, PAL para-aortic lymphadenectomy, BPR biopsy or pelvic lymph node removal, PR pathology report, NS not significant
a N (relative frequency)
bMedian (interquartile range)
Comparison of patients group with para-aortic lymph node surgery
| Tumor removal and/or para-aortic biopsy | Para-aortic lymphadenectomy |
| |
|---|---|---|---|
| Countrya | |||
| Mexico (INCan) | 5 (35.7) | 2 (33.3) | 0.26 |
| Colombia (ICLA) | 9 (64.3) | 4 (66.7) | |
| Age (years)b | 45 (40–45) | 44.5 (42–50) | 0.90 |
| BMIb | 26.55 (23.7–28.3) | 23.9 (22.5–32.7) | 0.60 |
| Histologya | |||
| Squamous | 6 (42.9) | 3 (50) | 0.02 |
| Adenocarcinoma | 5 (35.7) | 3 (50) | |
| Adenosquamous | 1 (7.1) | 0 | |
| Others | 2 (14.3) | 0 | |
| Initial clinical stagea | |||
| IB1 | 12 (85.7) | 6 (100) | <0.001 |
| IB2 | 2 (14.3) | 0 | |
| Tumor size (cm)b | 3.5 (2–4) | 3.15 (2.9–4) | |
| Tumor gradea | |||
| Well-differentiated | 4 (28.6) | 3 (50) | 0.95 |
| Moderately differentiated | 3 (21.4) | 3 (50) | |
| Poorly differentiated | 7 (0.5) | 0 | |
| LVSIa | 3 (21.4) | 0 | 0.09 |
| PR positive | 6 (42.9) | 1 (16.7) | 0.354 |
| Surgical time (min)b | 172.5 (90–195) | 120 (100–195) | 0.78 |
| Blood loss (mm)b | 100 (70–300) | 140 (100–250) | 0.72 |
| Blood transfusiona | 0 | 0 | NS |
| Others complicationsa | 0 | 1 (16.7) | <0.001 |
| Hospital stay (days)b | 2 (2–2) | 2 (2–3) | 0.44 |
| Neoadjuvant treatment term (weeks)b | 10.5 (8.2–14.2) | 10.5 (8–15.4) | 0.66 |
| Recurrencea | |||
| Local | 0 | 1 (16.7) | <0.001 |
| Regional | 3 (21.4) | 0 | |
| Distance | 3 (21.4) | 0 | |
Confidence interval 95%
BMI body mass index, Mod moderate, LVSI lymphovascular space involvement, PR pathology report
a N (relative frequency)
bMedian (interquartile range)
Fig. 1Overall survival (OS) in patients with pelvic lymph node procedure. Five-year OS in the LNB group was 55.5%, and in the BPL group 90.9% (p = 0.171)
Fig. 2Disease-free survival (DFS) in patients with pelvic lymph node procedure. Five-year DFS in the LNB group was 52%, and in the BPL group 60% (p = 0.265)
Fig. 3Overall survival (OS) in patients with para-aortic lymph node procedure. Five-year OS in the LNB group was 42.1%, and in the PAL group 100% (p = 0.126)
Fig. 4Disease-free survival (DFS) in patients with para-aortic lymph node procedure. Five-year DFS in the LNB group was 32.5%, and in the PAL group 80% (p = 0.437)